Related Experiment Video
Updated: Aug 5, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Emerging Clinical Applications of Ketamine and Esketamine Across Psychiatric Disorders
Rachel Fremont1, Marcella Corwin1, Greta Kandel1
1Dennis Charney, MD, Depression and Anxiety Discovery Center, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
Abstract:
Over the past 25 years, the field of psychiatry has seen a rapid expansion of ketamine treatment services offered for the off-label management of depression, anxiety, and other psychiatric disorders as well as the U.S. Food and Drug Administration's approval of intranasal esketamine, the S-enantiomer of ketamine, for treatment-resistant depression and suicidal depression. In this review, the authors describe recent advances in the use of ketamine and esketamine for the treatment of depression and other psychiatric disorders, new research on novel treatment targets, and emerging evidence about ketamine's potential as a prophylactic intervention. Key outstanding issues and limitations of current ketamine treatment also are discussed.
Related Concept Videos
Electroconvulsive Therapy
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Psychosis and Antipsychotic Drugs: Overview
Parenteral Anesthetics: Overview
